Q2 2021 Results - Reimagining Medicine

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis pipeline in Phase 1 (1 of 2) ADPT01 ADPT03 Oncology Code AAA603 AAA602 Name 177 Lu-NeoB 177Lu-PSMA-R2 ADPT01 ADPT03 CSJ137 CSJ137 DKY709 DKY709spartalizumab HDM201 HDM201 + MBG453, venetoclax JBH492 JBH492 JDQ443 JDQ443 KRAS Inhibitor JEZ567 JEZ567 CD123 CAR-T KAZ954 KAZ954 LXF821 LXF821 LXH254 LXH254 MAK683 MCM998 MIK665 MAK683 MCM998, LXG250 MIK665 NIS793 NIS793, spartalizumab Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA BCL11A Growth factor inhibitor Novel immunomodulatory agent MDM2 inhibitor EGFR CAR-T CRAF inhibitor EED inhibitor BCMA CAR-T, CD19 CAR-T MCL1 inhibitor TGFB1 inhibitor Indication(s) Multiple solid tumors Prostate cancer Colorectal cancer (combos) Sickle cell anemia Anaemia Cancers Haematological malignancy Haematological malignancy Solid tumors Acute myeloid leukaemia Solid tumors Glioblastoma multiforme Solid tumors (combo) Cancers Multiple myeloma Acute myeloid leukaemia (combo) Solid tumors NIZ985 NIZ985, spartalizumab NZV930 PDR001 PHE885 PHE885 SQZ622 SQZ622 TNO155 TNO155 VAY736 ianalumab + ibrutinib VOB560 VOB560 VPM087 WNT974 gevokizumab WNT974+ spartalizumab WVT078 WVT078 YTB323 YTB323 ± ibrutinib NZV930, spartalizumab, NIR178 spartalizumab IL-15 agonist CD73 antagonist PD1 inhibitor BCMA cell therapy CD123xCD3 modulator SHP2 inhibitor BAFF-R inhibitor IL-1 beta antagonist Porcupine inhibitor CD19 CAR-T Solid tumors Solid tumors Solid tumors (combo) Multiple Myeloma Acute myeloid leukaemia Solid tumors (single agent) Haematological malignancy Cancers Colorectal cancer, 1st line Solid tumors Multiple myeloma Haematological malignancy - 48 Investor Relations | Q2 2021 Results References Innovation: Clinical trials 38 lead indications Lead indication Solid tumors (combo) Solid tumors (combo) NOVARTIS | Reimagining Medicine

View entire presentation